Moleculin Biotech, Inc.
MBRXDrugs in Pipeline
4
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
How MBRX's past catalysts played out
Liposomal Annamycin Injection in combination with Cytarabine Injection
Acute Myeloid Leukaemia (AML)
Liposomal Annamycin (L-Annamycin)
Sarcoma,Soft Tissue
Liposomal Annamycin
Leukemia, Myeloid, Acute
MOL4239
Psoriasis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Liposomal Annamycin Injection in combination with Cytarabine Injection | Phase 3 | Acute Myeloid Leukaemia (AML) | - | - |
Liposomal Annamycin (L-Annamycin) | Phase 2 | Sarcoma,Soft Tissue | - | - |
Liposomal Annamycin | Phase 2 | Leukemia, Myeloid, Acute | - | - |
MOL4239 | Phase 2 | Psoriasis | - | - |
Acute Myeloid Leukaemia (AML)
1 drug in this indication
Leukemia, Myeloid, Acute
1 drug in this indication
Sarcoma,Soft Tissue
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Moleculin Biotech, Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in Moleculin Biotech, Inc.'s (MBRX) pipeline across Phase 3, Phase 2. Its lead program is Liposomal Annamycin Injection in combination with Cytarabine Injection (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Moleculin Biotech, Inc.'s next FDA catalyst?→
Moleculin Biotech, Inc.'s (MBRX) next tracked catalyst is a Earnings expected November 12, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track MBRX biotech catalysts?→
Add MBRX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Moleculin Biotech, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.